" class="no-js "lang="en-US"> Pheast Therapeutics - Medtech Alert
Monday, September 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Pheast Therapeutics | Pharmtech Focus

Pheast Therapeutics

About Pheast Therapeutics

Pheast Therapeutics

Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. Founded in 2020 and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is aiming to develop novel therapies for some of the most difficult-to-treat and aggressive cancers, as well as women’s cancers including ovarian cancer and breast cancer.

Related Story

Diseases

 Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer | Pharmtech Focus

Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer

April 27 2022

Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has […]